Literature DB >> 26541534

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

Dermot S O'Callaghan1, Elton Rexhepaj2, Kathy Gately3, Linda Coate4, David Delaney5, Dearbhaile M O'Donnell3, Elaine Kay6, Finbarr O'Connell3, William M Gallagher7, Kenneth J O'Byrne8.   

Abstract

The impact of host immunity on outcome in nonsmall cell lung cancer (NSCLC) is controversial. We examined the relationship between lymphoid infiltration patterns in NSCLC and prognosis.Tumour- and stroma-infiltrating CD3(+), CD8(+) and forkhead box P3 (Foxp3)(+) T-lymphocytes were identified using immunohistochemistry and a novel image analysis algorithm to assess total, cytotoxic and regulatory T-lymphocyte counts, respectively, in 196 NSCLC cases. The median cell count was selected as a cut-point to define patient subgroups and the ratio of the corresponding tumour islet:stroma (TI/S) counts was determined.There was a positive association between overall survival and increased CD8(+) TI/S ratio (hazard ratio (HR) for death 0.44, p<0.001) but an inverse relationship between Foxp3(+) TI/S ratio and overall survival (HR 4.86, p<0.001). Patients with high CD8(+) islet (HR 0.48, p<0.001) and Foxp3(+) stromal (HR 0.23, p<0.001) counts had better survival, whereas high CD3(+) and CD8(+) stromal counts and high Foxp3(+) islet infiltration conferred a worse survival (HR 1.55, 2.19 and 3.14, respectively). By multivariate analysis, a high CD8(+) TI/S ratio conferred an improved survival (HR 0.48, p=0.002) but a high Foxp3(+) TI/S ratio was associated with worse survival (HR 3.91, p<0.001).Microlocalisation of infiltrating T-lymphocytes is a powerful predictor of outcome in resected NSCLC.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26541534     DOI: 10.1183/13993003.00176-2014

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

1.  Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

Authors:  Jared Klarquist; Kristen Tobin; Peyman Farhangi Oskuei; Steven W Henning; Manuel F Fernandez; Emilia R Dellacecca; Flor C Navarro; Jonathan M Eby; Shilpak Chatterjee; Shikhar Mehrotra; Joseph I Clark; I Caroline Le Poole
Journal:  Cancer Res       Date:  2016-09-12       Impact factor: 12.701

2.  Tumor Microenvironment Mediators CD8+- and FOXP3+-Labeled T Lymphocytes Are Prospective Prognosticators in Curatively Treated Rectal Cancer Patients.

Authors:  Hala Zaghloul; Ahmed Abbas; Dina Abdulah
Journal:  J Gastrointest Cancer       Date:  2021-03

Review 3.  Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis.

Authors:  Sha Zhao; Tao Jiang; Limin Zhang; Hui Yang; Xiaozhen Liu; Yijun Jia; Caicun Zhou
Journal:  Oncotarget       Date:  2016-06-14

4.  How to evaluate the immune status of lung cancer patients before immunotherapy.

Authors:  Joanna Domagala-Kulawik; Agata Raniszewska
Journal:  Breathe (Sheff)       Date:  2017-12

5.  Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60.

Authors:  Feng Wang; Liqing Wang; Jian Wu; Ivan Sokirniy; Phuong Nguyen; Thomas Bregnard; Joseph Weinstock; Michael Mattern; Irina Bezsonova; Wayne W Hancock; Suresh Kumar
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

6.  The Clinicopathological and Prognostic Implications of FoxP3+ Regulatory T Cells in Patients with Colorectal Cancer: A Meta-Analysis.

Authors:  Peipei Xu; Wei Fan; Zheng Zhang; June Wang; Ping Wang; Yirong Li; Mingxia Yu
Journal:  Front Physiol       Date:  2017-11-21       Impact factor: 4.566

7.  Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity.

Authors:  Liqing Wang; Suresh Kumar; Satinder Dahiya; Feng Wang; Jian Wu; Kheng Newick; Rongxiang Han; Arabinda Samanta; Ulf H Beier; Tatiana Akimova; Tricia R Bhatti; Benjamin Nicholson; Mathew P Kodrasov; Saket Agarwal; David E Sterner; Wei Gu; Joseph Weinstock; Tauseef R Butt; Steven M Albelda; Wayne W Hancock
Journal:  EBioMedicine       Date:  2016-10-15       Impact factor: 8.143

8.  FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer.

Authors:  Shucai Yang; Yi Liu; Ming-Yue Li; Calvin S H Ng; Sheng-Li Yang; Shanshan Wang; Chang Zou; Yujuan Dong; Jing Du; Xiang Long; Li-Zhong Liu; Innes Y P Wan; Tony Mok; Malcolm J Underwood; George G Chen
Journal:  Mol Cancer       Date:  2017-07-17       Impact factor: 27.401

9.  The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells.

Authors:  Jiangzhou Peng; Zigang Yu; Lei Xue; Jiabin Wang; Jun Li; Degang Liu; Qiang Yang; Yihui Lin
Journal:  Mol Med Rep       Date:  2018-02-13       Impact factor: 2.952

Review 10.  Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer.

Authors:  Daniel R Principe; Lauren Chiec; Nisha A Mohindra; Hidayatullah G Munshi
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.